ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CPIX / dividends
ZYBT (41) FBIO (30) INCR (46) SPRO (40) ⌘ Pro Terminal β†’

Cumberland Pharmaceuticals Inc. (CPIX) Dividend Safety Gauge & 10-Year DRIP Compounder

$4.22 -10.02% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.14

Cumberland Pharmaceuticals Inc. (CPIX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $63.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CPIX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.22 (-10.02% 1D, market cap $63.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, CPIX ranks #540 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CPIX compare to ZYBT and FBIO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, ZYBT (Zhengye Biotechnology Holding Limited (Class A)) holds a D- grade (41/100 RQD, P/E N/A, ROIC -22.3%, cap $63.0M) and FBIO (Fortress Biotech Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $64.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CPIX?
β–Ό

Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.14 (-1.99%)🧬 Cannibal Buyback (-0.96% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 10.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (37/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- Β· Rk D-
Cash (6)Whales (4)SEC (7)Macro (9)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$10 Bull$4 Base$3 Bear
πŸ“¬ FREE CPIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CPIX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
πŸ” WHY CPIX SCORES 37/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (30% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy β€’ Cannibal Buyback (-0.96% YoY Shares)

β–² #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime Γ— Technicals: 32% of 52W Range β€’ RSI-14 at 32.7 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
45
Grade D$7.17+11% Next Q
Q2 (-2Q)
42
Grade D$7.96-37.8% Next Q
Q3 (-1Q)
40
Grade D$4.95-14.7% Next Q
Current
37
Grade D-$4.22-8.1% Hist 90D Ξ±
Trajectory: D (45) β†’ D- (37)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CPIX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CPIX currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.99) and Max Pain ($4.43) forces dealer call-delta covering toward $9.74.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CPIXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCPIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (11.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $29,699

Est. Year-10 Shareholder Yield: $535/yr
$11.2K
Yr 1
$12.4K
Yr 2
$13.9K
Yr 3
$15.5K
Yr 4
$17.2K
Yr 5
$19.2K
Yr 6
$21.4K
Yr 7
$23.9K
Yr 8
$26.6K
Yr 9
$29.7K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CPIX)

  • βœ“Walkthrough of CPIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CPIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.25%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $4.69H $4.69L $4.22C $4.22VOL 205.7K
RES: $8.67SUP: $4.14SMA50: $6.99SMA200: $5.52
$9.69$7.99$6.28$4.58$2.87RES $8.67SUP $4.14$4.222026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CPIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CPIX Butterfly Map β†’ + Track CPIX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CPIX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CPIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CPIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CPIX)

Health Care Rank #540 of 1015 βš”οΈ ZYBT vs CPIX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CPIX vs. ZYBT, FBIO, INCR, SPRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cumberland Pharmaceuticals Inc. (CPIX) ranks #540 by composite RQD confidence (37/100, grade D-) and #709 by equity capitalization ($63.2M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and β€” gross margin. INCR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CPIX at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CPIX ACTIVE
Cumberland Pharmaceuticals Inc.
D- 37/100 β€” 85.0% -16.4% -10.02% $63.2M Benchmark Subject
ZYBT
Zhengye Biotechnology Holding Limited (Class A)
D- 41/100 β€” 20.5% -22.3% +2.31% $63.0M /zybt-vs-cpix β†’
FBIO
Fortress Biotech Inc.
E 30/100 β€” 66.9% -35.0% +0.52% $64.4M /fbio-vs-cpix β†’
INCR
Intercure Ltd.
D 46/100 β€” β€” β€” +2.02% $60.8M /incr-vs-cpix β†’
SPRO
Spero Therapeutics Inc.
D- 40/100 7.5x β€” 26.6% -1.89% $60.6M /spro-vs-cpix β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001087294 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cumberland Pharmaceuticals Inc. (CPIX) reported GAAP revenue of $44.5M (+17.6% vs. FY2024 revenue of $37.9M , and +12.6% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of $4.9M, and free cash flow of $4.8M (+812.4% YoY). On the balance sheet, CPIX closed FY2025 with $76.8M in total assets against $0 in total debt (Altman Z-Score: 0.72, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.5M -$2.8M $4.9M $4.8M $76.8M β€”
FY2024 (FY) 2024-12-31 $37.9M -$6.5M -$612.2K -$678.6K $75.6M β€”
FY2023 (FY) 2023-12-31 $39.6M -$6.3M $6.1M $6.1M β€” β€”

3. CPIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CPIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.22 (-10.02% 1D, market cap $63.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, CPIX ranks #540 in composite RQD confidence.

How does CPIX compare to ZYBT and FBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CPIX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 85.0%, and ROIC of -16.4%. By comparison, ZYBT (Zhengye Biotechnology Holding Limited (Class A)) holds a D- grade (41/100 RQD, P/E N/A, ROIC -22.3%, cap $63.0M) and FBIO (Fortress Biotech Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $64.4M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CPIX?

Per CPIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001087294), Cumberland Pharmaceuticals Inc. generated $44.5M in revenue (+17.6% YoY), -$2.8M in net income, and $4.8M in free cash flow against $76.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CPIX trading relative to its 50-day, 200-day, and 52-week technical levels?

CPIX last traded at $4.22 (-10.02% on volume of 205,662 shares), positioning the stock -39.63% below its 50-day simple moving average ($6.99) and -23.55% below its 200-day simple moving average ($5.52). Across its 52-week range of $1.85 to $9.28, CPIX sits at the 31.9% percentile with a 14-day RSI of 32.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($3.69 to $4.75).

Direct Sub-Reports: CPIX RQD Cockpit CPIX 12M Forecast CPIX Earnings & Move CPIX Dividends & DRIP CPIX Insiders & 13F CPIX Whale Options CPIX Profit Sankey CPIX News & Why
ROARABLE RATING BRIEF β€’ RQD 37/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

CPIX β€” Cumberland Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cumberland Pharmaceuticals Inc. (CPIX) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $4.22 (-10.02% 1D, market capitalization $63.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -16.4%, gross margin of 85.0%, operating margin of -6.3%, and free cash flow yield of 7.42%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.72, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cumberland Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.1B. Per the market data, the company reports a gross margin of 85%. β€”: specific products, customer segments, or revenue model details.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cumberland Pharmaceuticals Inc. (CPIX) reported $44.5M in annual revenue (up from $37.9M in FY2024, +17.6% YoY) and -$2.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($39.6M revenue, -$6.3M net income) through FY2025, CPIX scaled operating cash flow to $4.9M and free cash flow to $4.8M, backed by $76.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 7.42% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.85 – $9.28 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against -6.3% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” The Butterfly Supply-Chain Graph lists no upstream or downstream dependencies, no sector correlations, and no proprietary signals for CPIX. Investors should note that the news flow concentrates on regulatory filings (the Duchenne cardiomyopathy NDA and Ifetroban filing plans), which are company-specific catalysts rather than supply-chain linkages.

  • Key Question #1: Can CPIX sustain or expand its -6.3% operating margin and -16.4% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $44.5M and free cash flow of $4.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CPIX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CPIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cumberland Pharmaceuticals Inc. (CPIX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CPIX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CPIX Bull vs. Bear Conversation Board β€” What's Your Call at $4.22?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CPIX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CPIX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER β€’ Cross-Asset Macro Desk πŸ‚ BULLISH 🎯 Target: $5.86 (+24.9%)
πŸ“Œ Pinned Debate

FY 2025 revenue grew to $44.5M with a positive 7.42% FCF yield and FCF of $4.8M, showing cash generation improving as operating losses

Don't sleep on CPIX's setup in Health Care. FY 2025 revenue grew to $44.5M with a positive 7.42% FCF yield and FCF of $4.8M, showing cash generation improving as operating losses narrowed to -$2.8M.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (37/100) backs up the fundamental quality.

ArenaChamp_24 πŸ‚ BULL

@MacroHawk_NYC Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.69 and keeping dry powder in case we test $4.36.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $3.94 (-16.0%)
Spot @ $4.69

An Altman Z-Score of 0.72 alongside ROIC of -16.4% and an operating margin of -6.3% leaves the balance sheet and returns under pressure

Here is the bear case nobody on the bull side wants to address on CPIX: An Altman Z-Score of 0.72 alongside ROIC of -16.4% and an operating margin of -6.3% leaves the balance sheet and returns under pressure while institutional flow scores only 4 of 20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE